Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX) following MESA OLE update

Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $46.00 price target on Edgewise Therapeutics (NASDAQ: EWTX)

The analyst commented, "This morning Edgewise reported an update from the ongoing MESA Open-Label Extension trial that continues to show stabilization of function (measured by NSAA) in participants on sevasemten versus the predicted functional decline observed in BMD natural history studies. Today's update from MESA show stabilization from ARCH-rollover patients out to 42 months vs. 36 months prior readout, and in CANYON-rollover patients up to 24 months from 18 months reported previously. We believe the data continue to support sevasemten's efficacy benefit in BMD, for which there are no approved therapies. Our recent investor conversations show that the focus for Edgewise continues to be on their HCM program, with less attention to the progress with sevasemten. Accordingly, we think the BMD program may be under the radar for many investors, and we believe there could be meaningful share upside with positive GRAND CANYON data in 4Q2026 that could be registration-enabling."

For an analyst ratings summary and ratings history on Edgewise Therapeutics click here. For more ratings news on Edgewise Therapeutics click here.

Shares of Edgewise Therapeutics closed at $28.66 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• American Resources receives Nasdaq notice for late 10-Q filing
• Edgewise Therapeutics (EWTX) PT Lowered to $48 at RBC Capital